All In Biotech

Drug Trial Radar · NCT01109030

Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Last checked: Nov 20, 2026Latest source record: May 9, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

50

Actual

Start

Apr 2010

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
Tehran University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Pioglitazone as an adjunct to Citalopram is effective in treatment of moderate to severe depression

Conditions

  • Major Depressive Disorder

Interventions

  • Pioglitazone+Citalopram+ChlordiazepoxideDrug

    Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks. Chlordiazepoxide 10 mg each night for first three weeks

  • Placebo+ Citalopram+ ChlordiazepoxideDrug

    Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks. Chlordiazepoxide 10 mg each night for first three weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Scores of Hamilton Depression Rating Scale (17 items) at the endTime frame: week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of psychiatry, Roozbeh psychiatric hospital, Tehran University of medical sciences

    Tehran, Tehran Province, Iran

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.